Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia

Dong-A ST Co., Ltd.223 enrolled

Overview

Comparison of the efficacy and safety of Cresnon® and Crestor® in patients with hyperlipidemia \- 8-week, active-controlled, open-label, randomized, parallelgroup, fixed-dose, noninferiority, multicenter, phase 4 design

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

223

Conditions

Hyperlipidemia

Interventions

Rosuvastatin(Cresnon®)DRUG

10mg

Rosuvastatin(Crestor®)DRUG

10mg

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 20 * Persons who have not reached LDL-C targeted level in accordance with the treatment guidelines for dyslipidemia released by Korean Society of Lipidology and Atherosclerosis

Locations (1)

Seoul National University Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

The percent change in LDL-C

Time frame: After taken medication for 8 weeks

Secondary Outcomes

The percent change in total cholesterol, Triglyceride, HDL-C, non-HDL-C, and non-HDL-C/HDL-C

Time frame: After taken medication for 8 weeks

The proportion of subjects reaching LDL-C targeted level in accordance with the treatment guidelines for dyslipidemia released by Korean Society of Lipidology and Atherosclerosis

Time frame: After taken medication for 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.